Spotlight session: Choosing the right modality to overcome the solid tumor challenge
Developing effective cell and gene therapies for solid tumors demands approaches that overcome the tumor microenvironment, ensure adequate targeting, and maintain safety margins. This spotlight session examines how modality choice influences translational fidelity, biomarker strategy, and clinical design when tackling solid tumor indications.
Key takeaways:
-
Compare modalities suited for addressing heterogeneity and immune evasion in solid tumors.
-
Assess strategies to enhance targeting and penetration within the tumor microenvironment.
-
Explore dose selection and safety margin considerations specific to solid tumor therapies.
-
Identify biomarkers that inform patient stratification and therapeutic monitoring.
-
Consider translational fidelity and predictive validity challenges in preclinical modeling of solid tumors.
